Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

• Published in: Clínica e investigación en arteriosclerosis (Internet, English ed.) English ed.), 2022-09, Vol.34 (5), p.245-252
• Main Authors: Seijas-Amigo, Jose, Gayoso-Rey, Mónica, Mauriz-Montero, María José, Suarez-Artime, Pedro, Casas-Martinez, Antonia, Dominguez-Guerra, María, Gonzalez-Freire, Lara, Estany-Gestal, Ana, Codero-Fort, Alberto, Rodriguez-Mañero, Moisés, Gonzalez-Juanatey, Jose Ramón
• Format: Article
• Language: English
• Subjects: Colesterol-LDL; COVID-19; Effectiveness-safety; Eficacia-seguridad; Inhibidores de la PCSK9; LDL-cholesterol; Original; PCSK9 inhibitors
• ISSN: 2529-9123; 2529-9123
• DOI: 10.1016/j.artere.2022.08.002

MEMOGAL study (NCT04319081) is aimed at evaluating changes in cognitive function in patients treated with PCSK9 inhibitors (PCSK9i). This is the first analysis: (1) discussion about the role of the Hospital Pharmacists during the pandemic, and also the assessment of the impact of COVID-19 in the lipid control; (2) descriptive analysis; (3) effectiveness in LDL cholesterol (LDL-c) reduction of alirocumab and evolocumab; (4) communicate PCSK9i safety. It is a prospective Real-World Evidence analysis of patients that take PCSK9i for the first time in the usual clinical practice, and they are included after the first dispensation in the public pharmacy consultations of 12 Hospitals in Galicia from May 2020 to April 2021. Baseline values of LDL-c are the previous values before taking PCSK9 and the follow-up values are in 6 months time. 89 patients were included. 86.5% with cardiovascular disease and 53.9% with statin intolerances. 78.8% of the patients were treated with high intensity statins. Statins most used were rosuvastatin (34.1%) and atorvastatin (20.5%). Baseline value of LDL-c was 148 mg/dl and the follow-up value was 71 mg/dl. The baseline value of patients treated with alirocumab (N = 43) was 144 mg/dl and 73 mg/dl in the follow-up. With evolocumab (N = 46) was 151 mg/dl in basaline and 69 mg/dl in follow-up. The LDLc- reduction was 51.21% with evolocumab and 51.05% with alirocumab. 43.1% of the patients showed values >70 mg/dl in six month time; 19.4% between 69 mg/dl and 55 mg/dl and 37.5% 50% of LDL-c. The adverse events were: injection point reaction (N = 2), myalgias (N = 1), flu-like symptoms (N = 1) and neurocognitive worsening (N = 1). (1) Despite the number of prescriptions was reduced because of the pandemic, the lipid control was not affected. (2) Half of the patients treated with PSCK9i is due to statins intolerance and the 86% is for secondary prevention. (2) The reduction results were similar to pivotal clinical trials. Despite this, 39% of the total of the patients and 60% of patients with dual teraphy did not reach the goal of ESC/EAS guidelines ( 50%). There were not significant differences between evolocumab and alirocumab: 51.21% vs 51.05% (P = .972). (3) There were not any adverse events of special interest. The possible neurocognitive worsening will be studied as the primary endpoint once the MEMOGAL study has been completed. El estudio MEMOGAL (N